Glimepiride 2 mg

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, University of Catanzaro

Conditions

Cardiovascular Risk FactorType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)

CompletedNCT01614769

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2012-07-18End: 2013-01-23Updated: 2018-08-16

Phase 4

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

CompletedNCT04183868

University of CatanzaroCardiovascular Risk Factor, Type 2 Diabetes

Start: 2016-04-30End: 2021-10-31Updated: 2023-01-18